Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Acquires 60,000 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $2.16 on Friday. The stock’s 50-day moving average is $2.81 and its 200 day moving average is $3.21. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.61 and a 1-year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. HC Wainwright cut their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, Guggenheim lowered their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.24.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $68,000. Charles Schwab Investment Management Inc. boosted its holdings in Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after acquiring an additional 91,152 shares during the period. Anfield Capital Management LLC grew its position in Zentalis Pharmaceuticals by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock worth $392,000 after acquiring an additional 64,659 shares during the last quarter. Ieq Capital LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $46,000. Finally, Savant Capital LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $72,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.